イギリス在住。学界と製薬産業両方の研究経験を持つ細胞生物学者。神経系の発達における軸索ガイダンスのアクチン細胞骨格と細胞接着分子の役割の研究で博士号取得し、その後も研究を進める。2001年にグラクソスミスクラインに加わり、神経変性疾患および精神疾患の目標識別と確認イニシアティブ、幹細胞を含む新薬発見戦略の開発に携わる。細胞生物学、分子生物学とタンパク質生化学技術の広い範囲をカバーする技術的専門知識に長けている。世界的査読付ジャーナルで筆頭著者として数々の論文を発表。

Dr. Lodge is a cell biologist with research experience in both academia and the pharmaceutical industry. For his PhD and postdoctoral work, he studied the roles of the actin cytoskeleton and cell adhesion molecules in axon guidance during nervous system development. Dr. Lodge joined GlaxoSmithKline in 2001, where he has been involved in target identification and validation initiatives for neurodegenerative and psychiatric diseases, and in developing drug discovery strategies involving stem cells. His technical expertise covers a broad spectrum of cell biology, molecular biology and protein biochemistry techniques. Dr. Lodge has published several first author publications in international peer-reviewed journals. He began editing for the Edanz Group in 2008.